mao-a

MAO A/HDAC-IN-1 is an effective monoamine oxidase A (MAO A) and HDAC dual inhibitor, which can be used for glioma research.

MAO A/HSP90-IN-2 (compound 4-C), a dual inhibitor of HSP90 and MAO A, exhibits IC50 values of 0.016 μM for MAO A and 4.58 μM for HSP90. This compound not only enhances HSP70 expression but also diminishes HER2 and phospho-Akt levels, and downregulates IFN-γ-induced PD-L1 expression in GL26 cells. Demonstrating efficacy against Temozolomide-sensitive and -resistant GBM cells, colon cancer, leukemia, non-small cell lung cancer, and other malignancies, MAO A/HSP90-IN-2 may also impede tumor immune evasion [1].

MAO A/HSP90-IN-1 (4-b) is a dual inhibitor of MAO A and HSP90, exhibiting IC50 values of 1.77 μM in glioblastoma (GBM) GL26 cells and 0.019 μM against HSP90α. This compound impairs the activities of MAO A, disrupts HSP90 binding, and downregulates both HER2 and phospho-Akt expressions, thereby inhibiting GBM growth. Additionally, it diminishes PD-L1 expression, thereby thwarting T cell activation and potential tumor immune evasion. MAO A/HSP90-IN-1 (4-b) is valuable for research into brain tumor-related diseases [1].

CX-157 (KP 157) is a novel monoamine oxidase-A (MAO-A) inhibitor for the study of depression-like neurological disorders and cancer.

Safinamide mesylate (EMD 1195686 mesylate) , a mesylate salt of Safinamide, can reversibly and specifically inhibit MAO-B (IC50: 98 nM), has 5918-fold selectivity against MAO-A.

Hydroxyamine hydrochloride(Hydroxylammonium chloride) is a selective and potent monoamine oxidase (MAO) inhibitor with inhibitory effects on platelet aggregation.Hydroxyamine hydrochloridee is an intermediate in organic synthesis and can be used to synthesize other active compounds.

Paeonol (Peonol) is an active extraction from Paeonia suffruticosa. Paeonol inhibits MAO-A and MAO-B with IC50 of 54.6 μM and 42.5 μM, respectively.

AChE/BChE/MAO-B-IN-1 is a reversible, non-time-dependent inhibitor of AChE, BChE and MAO-B that crosses the blood-brain barrier and exhibits inhibitory effects on hAChE, hBChE and hMAO-B with IC50s of 7.31, 0.56 and 26.1 μM, respectively. 1 had a neuroprotective effect and was not significantly cytotoxic.

2614W94 is a selective inhibitor of MAO-A with IC50 of 5 nM and Ki of 1.6 nM.

MAO-B-IN-9 is a monoamine oxidase B MAO-B inhibitor (IC50: 0.18 μM) that crosses the blood-brain barrier with potency, selectivity and time-dependence. MAO-B-IN-9 has neuroprotective effects against Aβ1-42-induced neuronal cell death, which may be related to the anti-aggregation effect of Aβ1-42.

MAO-B-IN-5 is a potent, selective and orally active MAO-B inhibitor with an IC 50 of 0.204 μM. MAO-B-IN-5 has the research potential in Parkinson's disease (PD) [1].

Esuprone (LU-43839) is a novel reversible and highly selective MAO-A inhibitor with anticonvulsant activity for the treatment of depression.

Milacemide is a glycine prodrug and MAO-B inhibitor. Milacemide has been studied for its effects on human memory and as a potential treatment for the symptoms of Alzheimer's disease.

Indantadol HCl (CHF-3381) is a NMDA antagonist and nonselective MAO inhibitor.

AnnH31 is a potent Dyrk1A inhibitor with an IC50 value of 81 nM.AnnH31 inhibits MAO-A with an IC50 of 3.2 μM.AnnH31 can be used as a probe to confirm the involvement of DYRK1A in cellular phosphorylation.

Bazinaprine is a selective, reversible monoamine oxidase inhibitor (MAOI) that is a candidate compound for the treatment of depression. Bazinaprine showed strong inhibitory effect on type A monoamine oxidase and weak inhibitory effect on type b monoamine oxidase. Bazinaprine is reversible in vivo, but not in vitro.

Tetrindole mesylate is a MAO-A inhibitor.

CR4056 (6-(1H-imidazol-1-yl)-2-phenylquinazoline) is a selective inhibitor of MAO-A with IC50 of 202.7 nM and a ligand of I2-imidazoline receptor with IC50 of 596 nM.

PSB-1434 is a selective and competitive monoamine oxidase B inhibitor.

(Z)-SU4312 is a inhibitor of MAO-B and NOS(IC50 value of 0.2 μM, 19.0μM,respectively).

Sembragiline (EVT-302) is a selective MAO-B inhibitor for the study of Alzheimer's disease (AD).

PSB-1491 is a selective and competitive monoamine oxidase B inhibitor with IC50 of 0.386 nM, >25000-fold selective versus MAO-A.

Rosmarinate acid(Rosemary acid) inhibits MAO-A, MAO-B and COMT enzymes with IC50s of 50.1, 184.6 and 26.7 μM, respectively

Atibeprone is a MAO-B inhibitor with antidepressant activity for the study of Parkinson's disease.

MAO-B-IN-1 is a monoamine oxidase B inhibitor and can be used for the research of neurological diseases.

Rosmarinic acid (Labiatenic acid) is widely found in plants and has antioxidant, anti-inflammatory, and antibacterial activities. It inhibits MAO-A, MAO-B, and COMT with IC50 of 50.1, 184.6, and 26.7 μM respectively.

1,4-Naphthoquinone (P-Naphthoquinone) was used as a potential inhibitor of monoamine oxidase and DNA topoisomerase activities[2]. It was also used to inhibit the acetyltransferase activity[1].

Jatrorrhizine (neprotin) is a protoberberine alkaloid isolated from Enantia chlorantha (Annonaceae) and other species. It was found to have antimicrobial and antifungal activity. It binds and noncompetitively inhibits monoamine oxidase (IC50 4 micromolar for MAO-A and 62 for MAO-B).

Pargyline (Pargylamine) is a monoamine oxidase inhibitor with antihypertensive properties.

Harmane (Loturine) is a bio-active β-Carboline and monoamine oxidase inhibitor found in coffee and tobacco smoke.

Harmine (Telepathine) is an alkaloid isolated from seeds of Peganum harmala.

MAO-B-IN-19, a selective MAO-B inhibitor, exhibits neuroprotective and anti-inflammatory properties and demonstrates an IC50 value of 0.67 μM [1].

Methylene Blue (Basic Blue 9) hydrate functions as an inhibitor of guanylyl cyclase (sGC), monoamine oxidase A (MAO-A), and NO synthase (NOS). This compound, known for its vasopressor activity, is widely utilized as a dye in various medical procedures. It operates via the nitric oxide synthase/guanylate cyclase signaling pathway to diminish prepulse inhibition and possesses the capacity to cross the blood-brain barrier. Methylene Blue hydrate acts as a REDOX cycling compound and inhibits Tau protein aggregation. Moreover, it is effective in reducing cerebral edema, damping microglial activation, and alleviating neuroinflammation, demonstrating its multifaceted therapeutic potential [1] [2] [3].

Chrysophanol-1-O-β-gentiobioside, an anthraquinone glycoside obtained from the seeds of Cassia obtusifolia, exhibits targeted inhibition of hMAO-A isozyme activity with an IC50 value of 96.15 μM.

PF-9601N showed high potency and selectivity as a MAO-BI (monoamine oxidase type B inhibitor) and also demonstrated remarkable neuroprotective properties in several in vivo and cellular models of PD.

Tranylcypromine (SKF 385), a potent monoamine oxidase (MAO) inhibitor [1], is used in medicinal applications.

WAY-620147 is a derivative of N-(2-morpholinoethyl)nicotinamide, which is able to inhibit Monoamine Oxidase.WAY-620147 has an IC50 value of 26 μM for MAO-A and 55 μM for MAO-B, and can be used for the study of neurological diseases.

MAO-B-IN-26 (Compound IC9) serves as both a MAO-B and acetylcholinesterase inhibitor. It safeguards SH?SY5Y cells from Aβ-induced toxicity, including morphological alterations, reactive oxygen species (ROS) production, and membrane damage, while also preventing Aβ-triggered autophagy and apoptosis. As such, MAO-B-IN-26 holds potential as a neuroprotective agent in the context of Alzheimer’s disease [1].

7-Hydroxy-3,4-dihydro-2(1H)-quinolinone is a weak MAO-A inhibitor(with an IC50 of 183 μM) .

Eprobemide (LIS 630) is a non-competitive reversible inhibitor of monoamine oxidase A (MAO-A).

(S)-Salsolidine, a chemical compound, functions as a weak inhibitor of monoamine oxidase (MAO), exhibiting an inhibition constant (K i ) of 63 μM. R enantiomer demonstrating a greater efficacy than (S)-Salsolidine, boasting a K i value of 26 μM compared to the S form.

Cudraflavone B has anti-proliferative activity, mouse brain monoamine oxidase (MAO) inhibitory effects, apoptotic actions in human gastric carcinoma cells and mouse melanoma cells, and hepatoprotective activity. It may be a lead for the development of a potential candidate for human oral squamous cell carcinoma cells.

MAO-B-IN-27 (Compound 12c), a monoamine oxidase B (MAO-B) inhibitor, exhibits a potent and selective inhibitory effect on hMAO-B, with an IC50 value of 8.9 nM, and is utilized in Parkinson's disease (PD) research [1].

Pulrodemstat (CC-90011) is a highly potent and selective inhibitor of lysine specific demethylase-1 (LSD1). It exhibits a reversible mode of action and can be administered orally. With an impressive IC50 of 0.25 nM, Pulrodemstat effectively suppresses the enzymatic activity of LSD1. Notably, it demonstrates minimal inhibition against LSD2, MOA-A, and MAO-B enzymes. Moreover, Pulrodemstat possesses remarkable anticancer properties, promoting differentiation in acute myeloid leukemia (AML) and small cell lung cancer (SCLC) cells.

(±)-Amiflamine (2-dimethylphenethylamine) is an inhibitor of reversible MAO-A.

PZ-1922 (Compound 16), able to cross the blood-brain barrier, is a dual antagonist for 5-HT6R and 5-HT3R with K i values of 17 nM and 0.45 nM, respectively. It also reversibly inhibits MAO-B with a pIC50 of 8.93. Moreover, PZ-1922 mitigates scopolamine (SCOP)-induced memory deficits in rats as observed in the novel object recognition (NOR) test and hinders Aβ-induced memory impairment in the T-maze test [1].

MAO-B-IN-30 is a selective and potent MAO-B inhibitor that crosses the blood-brain barrier with antiproliferative activity and inhibits both MAO-A and MAO-B.MAO-B-IN-30 reduces the levels of TNF-alpha, IL-6, and NF-kB in organisms, and can be used to study Parkinson's-type neurological disorders.

Bifemelane hydrochloride is a MAO inhibitor

Brofaromine (CGP 11305A) is an MAO inhibitor (IC50: 0.2 μM for MAO-A).

Tisolagiline (KDS2010), a reversible MAO-B inhibitor, is utilized in Parkinson's disease research [1].

Peptide5 acetate reduces animal swelling, astrogliosis, and neuronal cell death after spinal cord injury. Peptide5 acetate significantly reduces the degree of spinal cord injury (SCI) in a rodent ex vivo model.